WO2006002972A1 - Process for the preparation of gabapentin - Google Patents
Process for the preparation of gabapentin Download PDFInfo
- Publication number
- WO2006002972A1 WO2006002972A1 PCT/EP2005/007202 EP2005007202W WO2006002972A1 WO 2006002972 A1 WO2006002972 A1 WO 2006002972A1 EP 2005007202 W EP2005007202 W EP 2005007202W WO 2006002972 A1 WO2006002972 A1 WO 2006002972A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gabapentin
- hydroxide
- formula
- mixture
- process according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention relates to a new process for the preparation of gabapentin by the neutralization of the acid addition salt of gabapentin in an organic solvent or a mixture of organic solvents with a quaternary ammonium hydroxide. More particularly the invention relates to a process for the preparation of Gabapentin form II.
- Gabapentin of formula (1) is the generic name of a well-known anticonvulsant agent, described for example in the Merck Index, 13 th Edition (2001), page 767 (4342).
- gabapentin 1-(aminomethyl)-1-cyclohexane acetic acid
- Gapentin has been used for the treatment of cerebral disorders such as epilepsy, hypokinesia, faintness attacks and brain trauma.
- Commercially available gabapentin currently on the market is an anhydrous crystalline form that, hereinafter, will be referred to as form II.
- form II anhydrous crystalline form that, hereinafter, will be referred to as form II.
- Several other gabapentin polymorphic forms have been described in the literature, being the more important gabapentin monohydrate (form I 1 EP0340677) and gabapentin form III (W 098/28255).
- WO99/18063 discloses a multi step synthesis wherein gabapentin of formula (1) is obtained as a final product after the catalytic hydrogenation of chemical intermediates comprising a cyano group.
- the involvement of cumbersome multi-step synthesis, high pressure hydrogenation and use of cyanides or other toxic reagents make these processes difficult from the technical point of view.
- solutions of acid addition salts of gabapentin in water or in short chain alcohols are eluted through ion exchange columns to get solutions of gabapentin of formula (1) in a free amino acid form.
- the rather long elution time needed, the large volumes of water or alcohols that should be evaporated and the need to introduce a rinse of the column in order to maintain the exchange capacity make these processes difficult to scale up.
- the neutralization can be carried out with the use of a base (WO98/28255, US5362883, and US53191385).
- WO98/028255 discloses a process for preparing gabapentin of formula (1) consisting of dissolving gabapentin hydrochloride in a solvent and neutralizing it by addition of an amine in solution, said solvent being chosen in such a way that the amine hydrochloride formed during the neutralization is more soluble therein than the anhydrous gabapentin.
- a new form of anhydrous gabapentin named form III, is prepared in the neutralization process. It is necessary to reprocess this form III by digestion or recrystallization in another solvent, to be able to prepare the pharmaceutical grade anhydrous gabapentin base, which is named form Il in WO98/028255.
- This process does not require the use of ion exchange resins, but has the drawback that, unless closely adjusted amounts of neutralizing amine are used, the product obtained may be contaminated with appreciable amounts of the amine used in the neutralization and which have to be removed subsequently from the end product, by additional purification steps. Furthermore, this process also requires the preparation of an intermediate, the so-called form III, which has to be reprocessed, with the corresponding decrease in yield and productivity.
- US5362883 and US5319135 disclose that gabapentin among other products, may be prepared from the acid addition salts thereof, e.g., from the hydrochloride, by their neutralization with a long list of bases, among which there are the free amines, sodium hydroxide, potassium hydroxide, calcium hydroxide and basic ion exchange resins.
- bases among which there are the free amines, sodium hydroxide, potassium hydroxide, calcium hydroxide and basic ion exchange resins.
- Method F the examples (Method F) of said patents only describe the use of the said resins for neutralizing aqueous solutions of gabapentin hydrochloride, i.e., a method corresponding with the one already described for example in the aforementioned patent EP0340677.
- the obtained gabapentin is contaminated with mineral salts (by-products) insoluble in organic solvents.
- mineral salts by-products
- the only way of getting rid of these mineral salts is by adding water, but then the yield decreases due to the high solubility of gabapentin in water.
- the polymorph of gabapentin which is obtained is the monohydrate (Form I).
- WO00/001660 discloses a process for the preparation of gabapentin in anhydrous form (i.e. form II), without using monohydrate gabapentin (i.e. form I), by treating an aqueous suspension of gabapentin with 2-methoxyethanol or 2-ethoxyethanol and crystallizing with an alcoholic solvent.
- this process the isolation of gabapentin monohydrate is avoided since water is eliminated by azeotropic distillation, however big volumes of water should be distilled in order to be removed.
- the present invention provides a new and straightforward process for the preparation of gabapentin by the neutralization of an acid addition salt of gabapentin in an organic solvent or a mixture of organic solvents with a quaternary ammonium hydroxide.
- This process avoids the several drawbacks associated with the aforementioned processes; multistep synthesis, isolation of intermediates (monohydrate or crude gabapentin), evaporation of larges volumes of solvents.
- quaternary ammonium hydroxide as neutralizing agent according to the invention brings the advantage to form by-products (quaternary ammonium salt) that will remain soluble in the reaction organic solvent. Accordingly, the by products could be easily eliminated after filtration and will not contaminate the gabapentin.
- the object of the present invention is related to a process for the preparation of gabapentin in anhydrous or hydrated form of formula (1),
- XH represents a mineral acid or a strong organic acid, in an organic solvent or a mixture of organic solvents with a quaternary ammonium hydroxide and
- a stoichiometric amount of a quaternary ammonium hydroxide is added during the neutralization step (a).
- the neutralization of an acid addition salt of gabapentin according to the invention can be easily monitored e.g. by measuring the pH of the resulting solution. Accordingly, the exact stoichiometric amount of quaternary ammonium hydroxide can be added for the completion of the reaction.
- the neutralization is completed when the pH of the solution is between 6.5 and 8.5, preferably between 7.0 and 8.0.
- the neutralization step (a) comprises the following sub-step: (a1 ) Addition of a quaternary ammonium hydroxide to a solution of an acid addition salt of gabapentin of formula (2) in a first organic solvent, preferably a C1-C6 lower alkyl alcohol or a mixture thereof., preferably at room temperature, (a2) Heating the resulting solution at a temperature from 30 to 68°C, preferably from 55 to 65°C, (a3) Adding, preferably at the same temperature, a second organic solvent, preferably a
- separation step (b) comprises the filtration followed by the washing of the resulting solid gabapentin of formula (1) with an organic solvent or a mixture thereof. More preferably, the organic solvent is a C1-C6 lower alkyl alcohol or a mixture thereof.
- the gabapentin of formula (1) prepared according to the invention may be further purified by methods known in the art, such as recrystallization or slurrying the gabapentin in a suitable organic solvent or a mixture thereof.
- the gabapentin is recrystallized in a C1-C6 lower alkyl alcohol or a mixture thereof.
- Preferred mineral acid are selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid.
- the commercially available gabapentin hydrochloride is preferred as starting material according to the invention.
- Other acid addition salts of gabapentin of formula (2) can be prepared for example according to WO03/089403 or from gabapentin monoamide as described in WO 03/070683.
- Preferred strong organic acids are selected from the group consisting of paratoluensulphonic acid and formic acid.
- the quaternary ammonium hydroxide is of formula (3)
- R-i, R 2 , R 3 and R 4 represents each independently a C1-C6 alkyl; a benzyl; an aryl, particularly a phenyl; a substituted C1-C6 alkyl or a substituted aryl.
- Particularly preferred quaternary ammonium hydroxide are selected from the group consisting of tetramethylammonium hydroxide, tetraethylammonium hydroxide, tetrabutylammonium hydroxide, tetrapropylammonium hydroxide, benzyltrimethylammonium hydroxide and benzyltriethylammonium hydroxide.
- tetramethylammonium hydroxide, tetraethylammonium hydroxide and tetrabutylammonium hydroxide All those preferred quaternary ammonium hydroxide are commercially available.
- the quaternary ammonium salt is used in solid form or dissolved in an organic solvent or mixture thereof, preferably in alcoholic solvents or mixture thereof.
- Preferred alcoholic solvents used in the neutralization and in the isolation step are C1-C6 alkyl alcohols solvents or mixture thereof.
- Preferred C1-C6 alkyl alcohols include, but are not limited to, methanol, ethanol, 2-propanol (isopropanol), butanol (such as n-butanol, isobutanol, and t-butanol) and isoamyl alcohol (isopentanol) or a mixture thereof.
- Preferred C1-C6 alkyl alcohols include methanol, ethanol, isopropanol or a mixture thereof.
- C1-C6 alkyl alcohol solvent of the neutralizing step (a) and the isolating step (b) is selected from the group consisting of methanol, ethanol and isopropanol or a mixture thereof.
- methanol, isopropanol or a mixture thereof are particularly preferred in the separating step (b) according to the invention.
- Any other polymorph or hydrate of gabapentin of formula (1) can also be isolated as end product by using specific ratio of organic solvents or mixture thereof as disclosed in the prior art.
- gabapentin form III is isolated if the product is crystallized from isopropanol and gabapentin monohydrate could be obtained if water is used.
- gabapentin of formula (1) isolated after filtration and washing without any further purification gives an assay by HPLC higher than 99% with a content of lactam lower than 0.1 %.
- the isolation yield is between 70 and 80%.
- a second crop can be isolated from the mother liquors giving an overall yield higher than 90%. Good results are obtained by isolating gabapentin hydrochloride from the mother liquors.
- Example 1 Preparation of gabapentin form Il from gabapentin hydrochloride using tetramethylammonium hydroxide in solid form
- Example 2 Preparation of gabapentin form Il from gabapentin hydrochloride using tetrabutylammonium hydroxide.
- the yield of the first crop is 76%. Assay by HPLC: higher than 99%. Lactam content below
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05766090A EP1765767A1 (en) | 2004-07-05 | 2005-07-04 | Process for the preparation of gabapentin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0415076.9 | 2004-07-05 | ||
GBGB0415076.9A GB0415076D0 (en) | 2004-07-05 | 2004-07-05 | Process for the preparation of gabapentin |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006002972A1 true WO2006002972A1 (en) | 2006-01-12 |
Family
ID=32843618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/007202 WO2006002972A1 (en) | 2004-07-05 | 2005-07-04 | Process for the preparation of gabapentin |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1765767A1 (en) |
GB (1) | GB0415076D0 (en) |
WO (1) | WO2006002972A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106217A1 (en) * | 2007-02-28 | 2008-09-04 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin by liquid-liquid extraction |
WO2009087005A2 (en) * | 2008-01-10 | 2009-07-16 | Nicox S.A. | Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB707903A (en) * | 1951-05-10 | 1954-04-28 | British Drug Houses Ltd | Improvements in or relating to the resolution of isomeric mixtures of 1-p-nitrophenyl-2-aminopropane-1,3-diol |
WO1998028255A1 (en) * | 1996-12-24 | 1998-07-02 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
US6255526B1 (en) * | 1996-12-24 | 2001-07-03 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
US6518456B1 (en) * | 2001-12-21 | 2003-02-11 | Procos S.P.A. | Process for the production of 1-(aminomethyl)-cyclohexyl-acetic acid in pure form |
WO2003070683A1 (en) * | 2002-02-22 | 2003-08-28 | Shasun Chemicals And Drugs Limited | Preparation of new mineral acid addition salts of gabapentin |
WO2004101489A1 (en) * | 2003-05-19 | 2004-11-25 | Shasun Chemicals And Drugs Limited | Process for the preparation of gabapentin |
WO2004110981A1 (en) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | A process for the preparation of gabapentin form-ii |
-
2004
- 2004-07-05 GB GBGB0415076.9A patent/GB0415076D0/en not_active Ceased
-
2005
- 2005-07-04 WO PCT/EP2005/007202 patent/WO2006002972A1/en not_active Application Discontinuation
- 2005-07-04 EP EP05766090A patent/EP1765767A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB707903A (en) * | 1951-05-10 | 1954-04-28 | British Drug Houses Ltd | Improvements in or relating to the resolution of isomeric mixtures of 1-p-nitrophenyl-2-aminopropane-1,3-diol |
WO1998028255A1 (en) * | 1996-12-24 | 1998-07-02 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
US6255526B1 (en) * | 1996-12-24 | 2001-07-03 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin |
US6518456B1 (en) * | 2001-12-21 | 2003-02-11 | Procos S.P.A. | Process for the production of 1-(aminomethyl)-cyclohexyl-acetic acid in pure form |
WO2003070683A1 (en) * | 2002-02-22 | 2003-08-28 | Shasun Chemicals And Drugs Limited | Preparation of new mineral acid addition salts of gabapentin |
WO2004101489A1 (en) * | 2003-05-19 | 2004-11-25 | Shasun Chemicals And Drugs Limited | Process for the preparation of gabapentin |
WO2004110981A1 (en) * | 2003-06-12 | 2004-12-23 | Matrix Laboratories Ltd | A process for the preparation of gabapentin form-ii |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106217A1 (en) * | 2007-02-28 | 2008-09-04 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin by liquid-liquid extraction |
WO2009087005A2 (en) * | 2008-01-10 | 2009-07-16 | Nicox S.A. | Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain |
WO2009087005A3 (en) * | 2008-01-10 | 2009-12-23 | Nicox S.A. | Composition comprising a nitrooxyderivative of acetaminophen and a anticonvulsant drug for the treatment of neuropathic pain |
Also Published As
Publication number | Publication date |
---|---|
GB0415076D0 (en) | 2004-08-04 |
EP1765767A1 (en) | 2007-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101795096B1 (en) | Process for preparation of optically active diamine derivative salt | |
US7655806B2 (en) | Process for purification of anastrozole | |
JP5410578B2 (en) | Improved process for producing cilastatin acid | |
US20090253746A1 (en) | Synthesis and Preparations of Intermediates and New Polymorphs Thereof Useful For The Preparation Of Donepezil Hydrochlcoride | |
US8378106B2 (en) | Method for preparing argatroban monohydrate and a process for its synthesis | |
US20090326266A1 (en) | Process for the preparation of gabapentin | |
US7098362B2 (en) | Processes for the preparation of gabapentin | |
EP2608791B1 (en) | A process for the preparation of imatinib base | |
EP1765767A1 (en) | Process for the preparation of gabapentin | |
US7417166B2 (en) | Process for the preparation of gabapentin | |
US7071356B1 (en) | Process for the preparation of 1-(aminomethyl) cyclohexaneacetic acid | |
US7476760B2 (en) | Purification and production methods of 1-aminocyclopropanecarboxylic acid | |
US8569544B2 (en) | Process for preparation of benzphetamine and its pharmaceutically acceptable salts | |
EP3031800B1 (en) | Process for the preparation of high purity miglustat | |
JP3655463B2 (en) | Process for producing nitroguanidines | |
JP2023077019A (en) | METHOD FOR PURIFYING Z-α-METHOXYIMINO-2-FURANACETATE AMMONIUM SALT | |
US20070043236A1 (en) | Process for preparation of gabapentin | |
EP1636163A1 (en) | Process for the preparation of gabapentin | |
JP2001328983A (en) | Method for producing disubstituted nitroguanidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005766090 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005766090 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2005766090 Country of ref document: EP |